A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Sj?gren's Disease With Moderate to Severe Symptom Burden

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are:
* Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain?
* Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's?
* What are the blood levels of RSLV-132 over time?
* What is the immune (antibody) response in the body to RSLV-132?
* What is the safety profile of RSLV-132?
Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS.
Participants will:
Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device

开始日期2024-12-01

申办/合作机构

Resolve Therapeutics LLC

NCT04944121

/ Completed临床2期

A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)

The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome

开始日期2021-06-25

申办/合作机构

Resolve Therapeutics LLC

NCT03247686

/ Completed临床2期

A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome

The present study will examine the role of circulating RNA complexed with autoantibodies and immune complexes and its role in activation of inflammatory pathways in patients with primary Sjogren's syndrome. The study will be conducted in a subset of Sjogren's patients who have elevated levels of autoantibodies and a pattern of elevated interferon-stimulated gene expression in blood cells. A number of biochemical and clinical parameters will be analyzed to determine the potential therapeutic utility of nuclease therapy in Sjogren's syndrome.

开始日期2017-02-01

申办/合作机构

Resolve Therapeutics LLC

[+2]

100 项与 RSLV-132 相关的临床结果

登录后查看更多信息

100 项与 RSLV-132 相关的转化医学

登录后查看更多信息

100 项与 RSLV-132 相关的专利（医药）

登录后查看更多信息

项与 RSLV-132 相关的文献（医药）

2024-09-26·CLINICAL INFECTIOUS DISEASES

Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection: A Randomized Phase 2 Trial of RSLV-132

Article

作者: Boonyaratanakornkit, Jim B ; Andrews, James S ; Allen, Suzanne ; Posada, James A ; Krusinska, Eva

Abstract:

Background:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and RNA debris persist in viral reservoirs for weeks to months following infection, potentially triggering interferon production and chronic inflammation. RSLV-132 is a biologic drug composed of catalytically active human RNase1 fused to human IgG1 Fc and is designed to remain in circulation and digest extracellular RNA. We hypothesized that removal of SARS-CoV-2 viral RNA from latent reservoirs may improve inflammation, neuroinflammation, and fatigue associated with post-acute sequelae of SARS-CoV-2 infection (PASC).

Methods:

This was a phase 2, double-blind, placebo-controlled randomized clinical trial in participants with a 24-week history of PASC and severe fatigue. The primary endpoint of the trial assessed the impact of 6 intravenous doses of RSLV-132 on the mean change from baseline at day 71 in the Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a (PROMIS Fatigue SF 7a).

Results:

A statistically significant difference on day 71 was not observed with respect to the primary or secondary endpoints. This was likely due to a placebo response that increased during the trial. Statistically significant improvement in fatigue as measured by the PROMIS Fatigue SF 7a, Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue), and Physicians Global Assessment (PGA) instruments were observed earlier in the trial, with women demonstrating greater responses to RSLV-132 than men.

Conclusion:

While fatigue was not statistically significantly improved at Day 71, earlier timepoints revealed statistically significant improvement in fatigue and physician global assessment. The data suggest eliminating latent viral RNA by increasing serum RNase activity may improve fatigue in PASC patients. Women may respond better to this approach than men. Future studies will aim to confirm these findings.

2024-02-01·Lupus science & medicine

Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132

Article

作者: Posada, James ; Werth, Victoria P ; Burge, Daniel J ; Boackle, Susan A

Background:

Circulating, extracellular RNA is the primary trigger of type I interferon in systemic lupus erythematosus (SLE), and interferon is known to play a central pathogenic role in the disease. RSLV-132 is a catalytically active human RNase molecule fused to human IgG1 Fc designed to digest RNA and thereby decrease the chronic inflammation associated with SLE. The drug was evaluated in a cohort of patients with SLE with moderate-severe cutaneous disease activity and the presence of RNA immune complexes. The primary objective of the study was the assessment of the impact of 13 doses of 10 mg/kg RSLV-132 over 6 months on the mean Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) score.

Methods:

Sixty-five patients meeting the entry criteria of a baseline CLASI score of 10 or greater and positivity of at least one of five autoantibodies to RNA-binding proteins (SM/RNP, SSA/Ro, SSB/La, Sm, RNP) were randomly assigned (2:1) to receive 13 doses of RSLV-132 10 mg/kg or placebo, respectively. Participants received study drug for 24 weeks on days 1, 8, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141 and 155 with an end-of-treatment visit on day 169 and a follow-up visit at the end of the study on day 215. The primary objective was assessed on days 85 and 169. Secondary objectives included assessment of systemic disease activity using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), the British Isles Lupus Assessment Group 2004 Index and the Physician’s Global Assessment. Data from these instruments were used to calculate the SLE Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) scores.

Results:

The mean CLASI score change from baseline at day 169 was −5.7 (±7.0) in the placebo group and −6.2 (±8.5) in the RSLV-132 group. A subgroup of participants with moderate-severe systemic disease activity and high baseline SLEDAI scores (≥9) were analysed with respect to BICLA and SRI-4 responses. The RSLV-132 treated participants in the high SLEDAI subgroup had a greater percentage of BICLA responses (62% vs 44%) and SRI-4 responses (23% vs 11%) as compared with placebo. A second subgroup of participants with high baseline CLASI scores (≥21) were analysed with respect to BICLA and SRI-4 responses. The RSLV-132 treated participants in the high CLASI subgroup had a greater percentage of BICLA responses (28% vs 8%) and SRI-4 responses (39% vs 8%) as compared with placebo.

Conclusions:

Six months of RSLV-132 therapy consisting of a weekly loading dose of RSLV-132 for 1 month, followed by 5 months of biweekly administrations did not significantly improve the mean CLASI score relative to placebo in this cohort of patients with SLE. The study entry criteria selected patients with moderate-severe cutaneous disease activity and no minimum SLEDAI score, which resulted in a wide range of systemic disease activity from inactive to severe as measured by SLEDAI. When the participants with higher SLEDAI and CLASI scores were analysed, a trend towards clinical improvement favouring RSLV-132 was observed. The results warrant further evaluation of RSLV-132 in SLE and suggest that patients with more active systemic disease are most likely to benefit from RNase therapy.

2021-01-01·Arthritis & rheumatology (Hoboken, N.J.)1区 · 医学

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial

1区 · 医学

Article

作者: Valadkhan, Saba ; Barone, Francesca ; Posada, James ; Gallagher, Peter ; Davies, Kristen ; Ng, Wan‐Fai ; Wilson, Douglas ; Fisher, Benjamin A. ; Burge, Daniel ; Jobling, Kerry ; Tarn, Jessica ; Casement, John

Objective:

To assess the safety and efficacy of RSLV‐132, an RNase Fc fusion protein, in a phase II randomized, double‐blind, placebo‐controlled clinical trial in patients with primary Sjögren’s syndrome (SS).

Methods:

Thirty patients with primary SS were randomized to receive treatment with RSLV‐132 or placebo intravenously once per week for 2 weeks, and then every 2 weeks for 12 weeks. Eight patients received placebo and 20 patients received RSLV‐132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren’s Syndrome Disease Activity Index, EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST).

Results:

Patients randomized to receive RSLV‐132 experienced clinically meaningful improvements in the ESSPRI score (P = 0.27), FACIT‐F score (P = 0.05), ProF score (P = 0.07), and DSST (P = 0.02) from baseline to day 99, whereas patients who received placebo showed no changes in any of these clinical efficacy measures. This improvement was significantly correlated with increased expression of selected interferon‐inducible genes (Pearson’s correlations, each P < 0.05).

Conclusion:

Administration of RSLV‐132 improved severe fatigue, as determined by 4 independent patient‐reported measures of fatigue, in patients with primary SS.

项与 RSLV-132 相关的新闻（医药）

2025-05-28

·Business Wire

Resolve Therapeutics and Duke Medical School Initiate Observational Study of Cell-free RNA in Polytrauma Patients

MIAMI--(BUSINESS WIRE)--Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, today announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma www.resolvetherapeutics.com. A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of these patients experience poor clinical outcomes due to Systemic Inflammatory Response Syndrome (SIRS). The mechanism of SIRS in polytrauma patients is not completely understood but the current view holds that that massive tissue injury results in the release of large amounts of RNA into the blood overwhelming the activity of circulating RNase, which protects cells from the inflammatory effects of cfRNA under normal circumstances. The accumulating cfRNA activates several key mechanisms driving local and systemic inflammation which leads to increased morbidity and mortality. “Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,” said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University. Working closely with the world’s foremost trauma surgeons at Duke University, Resolve and Duke will conduct an observational study to analyze the presence, structure, and drug targeting of cfRNA in a selected population of polytrauma patients. Based on the results of this work, a proof-of-concept clinical trial with RSLV-132 (a fully human, catalytically active, RNase Fc fusion protein) may be undertaken seeking to improve clinical outcomes for polytrauma patients by removing circulating inflammatory nucleic acids. “We are thrilled to work with the world class physician scientists within the Duke University School of Medicine and are hopeful our work together may lead to an improvement in the outcome for patients with polytrauma,” commented Dr. James Posada chief executive officer of Resolve Therapeutics. “Duke Surgery offers a unique environment, coupling state of the art patient care with basic research expertise and infrastructure to enable systematic molecular analysis of plasma-borne inflammatory nucleic acids.” “Preventing systemic inflammation in polytrauma would be a large step forward in the treatment paradigm for these patients,” said Allan D. Kirk, MD, PhD, Chair of the Department of Surgery at Duke University. “We look forward to the collaboration with Resolve and learning more about the underlying mechanisms of inflammation in critically injured patients,” he added. About RSLV-132 RSLV-132 is a safe, fully-human, non-immunosuppressive, non-immunogenic, biologic drug with a three-week serum half-life. The drug is comprised of catalytically active human RNase fused to an engineered Fc region of human IgG1. It is designed to remain in circulation and digest extracellular pathogenic RNA in diseases where the presence of cfRNA drives the inflammatory process. RSLV-132 has proven safe in five clinical trials and has demonstrated improvement in autoimmune symptoms in phase 2 clinical trials in both systemic lupus erythematosus and Sjogren’s syndrome. About Resolve Therapeutics Resolve is a biopharmaceutical company at the forefront of the emerging field of cell-free nucleic acids in disease. We are developing RSLV-132 and RSLV-145 in a broad range of acute and chronic diseases that are driven by cell-free RNA, cell-free DNA, and Neutrophil Extracellular Traps (NETs). For more information or to discuss our programs please visit: https://resolvetherapeutics.com/

临床2期临床结果siRNA

2024-05-13

·PRNewswire

Resolve Therapeutics Publishes Results of RSLV-132 Phase 2 Long COVID Study

MIAMI, May 13, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development company pioneering transformative therapies for autoimmune and post-viral illnesses, today announced the publication of its phase 2 long COVID results in Clinical Infectious Diseases. The publication entitled "Assessment of the Impact of RNase in Patients with Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection (PASC): A randomized phase 2 trial of RSLV-132" evaluated the impact of RNase in one hundred and eight patients diagnosed with COVID-19 at least 6 months prior to baseline and with a history of continuous, severe fatigue. Participants received 6 doses of RSLV-132 or placebo over two months. The study measured fatigue and overall disease activity using the PROMIS SF 10a, FACIT-Fatigue, and physician's global assessment. Approximately 18 million Americans suffer the debilitating effects of long COVID. The most common symptoms are extreme fatigue, brain fog, immune dysregulation and depression or anxiety. Despite the large unmet medical need, A recent editorial in The Lancet identified only 12 pharmacological interventional clinical trials in development. Thus, very little progress has been made towards identifying drugs to treat the cardinal symptoms of long COVID. RSLV-132 has demonstrated significant clinical activity in improving autoimmune-related fatigue in Sjogren's syndrome. Results from the current long COVID phase 2 study suggest patients suffering from long COVID may also benefit from the removal of circulating RNA. "We are encouraged by the potential for RSLV-132 to improve the debilitating fatigue suffered by so many long COVID patients" commented Dr. James Posada chief executive officer of Resolve Therapeutics. "Interestingly, our data further suggests that women may respond better to RSLV-132 and digestion of latent viral RNA than men" added Dr. Posada. About RSLV-132 RSLV-132 is a non-immunosuppressive, biologic drug comprised of catalytically active human RNase1 fused to the Fc region of human IgG1. It is designed to remain in serum circulation and digest extracellular pathogenic RNA. RNA is the primary trigger of interferon and cytokine production that drives chronic inflammation in diseases such as SLE, Sjogren's. Recent studies suggest that RNA may play a role in post-viral illnesses such as PASC and ME/CFS as well. Therefore, removing it from circulation may decrease inflammation and improve the symptoms associated with these diseases. About Resolve Therapeutics Resolve is a private biotech company pioneering a transformative approach to autoimmune and post-viral diseases. The company is leveraging the extensive body of scientific discoveries that demonstrate the central role of pathogenic RNA molecules, weather self-derived or from viral sources, in driving inflammatory and neuroinflammatory symptoms. Resolve is actively developing RSLV-132 in mid-stage clinical development programs including SLE, Sjogren's syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). For more information please visit: Contact: James Posada Resolve Therapeutics 208-727-7010 [email protected] SOURCE Resolve Therapeutics, LLC

临床2期临床结果siRNA

2024-02-12

·PRNewswire

Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

MIAMI, Feb. 12, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine. The publication entitled "Evaluation of RNase therapy in systemic lupus erythematosus: a randomized phase 2a clinical trial of RSLV-132" describes a proof-of-concept study in SLE patients with moderate-severe cutaneous disease activity. The findings suggest that patients with Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) scores above nine respond preferentially to digestion of extracellular RNA as compared to patients with lower SLEDAI-2k scores less than nine. "We would like to express our deepest gratitude to the patients that participated in the study" commented Dr. James Posada chief executive officer of Resolve Therapeutics. "Mounting evidence substantiates the importance of extracellular RNA as a drug target in autoimmune diseases such as SLE and Sjogren's. Our study demonstrates the potential benefit of digesting circulating pathogenic RNA in selected SLE patients with active systemic disease and circulating RNA-containing autoantibodies" added Dr. Posada. About RSLV-132 RSLV-132 is a non-immunosuppressive, biologic drug comprised of catalytically active human RNase1 fused to the Fc region of human IgG1. It is designed to remain in serum circulation and digest extracellular pathogenic RNA in patients with autoimmune diseases. RNA is the primary trigger of interferon production and drives chronic inflammation in autoimmune diseases such as SLE and Sjogren's, therefore removing it from circulation may decrease inflammation and improve the symptoms associated with these autoimmune diseases. About Resolve Therapeutics Resolve is a private biotech company pioneering a completely new approach to autoimmune disease. The company is leveraging the extensive body of scientific discoveries that demonstrate the central role of pathogenic RNA molecules in autoimmune disease. Resolve is actively developing RSLV-132 in mid-stage clinical development programs icluding SLE, Sjogren's syndrome, and post-acute sequelae of SARS-CoV-2 infection (PASC). For more information please visit: Contact: James Posada Resolve Therapeutics 208-727-7010 [email protected] SOURCE Resolve Therapeutics, LLC

临床2期临床结果siRNA

100 项与 RSLV-132 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心血管疾病	临床2期	美国	Resolve Therapeutics LLC	2024-12-01
新冠肺炎后遗症	临床2期	美国	Resolve Therapeutics LLC	2021-06-25
原发性干燥综合征	临床2期	英国	Resolve Therapeutics LLC	2017-02-01
系统性红斑狼疮	临床2期	美国	Resolve Therapeutics LLC	2016-01-03
蛛网膜下腔出血	临床前	美国	Resolve Therapeutics LLC	2024-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03247686 (RSLV-132, CTgov)	临床2期	原发性干燥综合征	28	Placebo (Placebo)	繭簾獵鏇醖襯鑰鹽觸廠(築觸醖構觸壓鹹選網淵) = 壓淵鹹衊構壓膚遞鹹糧製衊獵膚製艱簾蓋遞窪 (醖積醖窪積鬱齋糧醖襯, 0.1151235) 更多	-	2021-04-02
				RSLV-132 (RSLV-132)	鹹廠艱積鹽膚窪蓋夢淵(艱鹽夢窪衊齋膚齋餘窪) = 廠艱壓壓鹹鏇壓襯衊糧觸獵餘範網網齋壓積蓋 (淵衊鹹鹽憲鬱範醖壓襯, 3.8) 更多
NCT02660944 (CTgov)	临床2期	系统性红斑狼疮	64	RSLV-132 (RSLV-132)	糧鹽積廠製積築膚製鑰(選艱製憲顧築鏇顧餘鹹) = 憲餘餘網鏇鹹範襯窪選窪夢醖鹽窪遞築簾製廠 (積積壓鑰夢廠簾選淵糧, 6.7) 更多	-	2021-03-10
				Placebo (Placebo)	糧鹽積廠製積築膚製鑰(選艱製憲顧築鏇顧餘鹹) = 簾艱範鏇遞繭範夢願觸窪夢醖鹽窪遞築簾製廠 (積積壓鑰夢廠簾選淵糧, 6.2) 更多
NCT03247686 (Pubmed \| Arthritis Rheumatol) 人工标引	临床2期	疲劳 \| 原发性干燥综合征	28	RSLV-132	選夢艱衊蓋鑰憲願遞鹽(鏇醖蓋艱衊選蓋憲築觸): P-Value = 0.02 更多	积极	2021-01-01
				Placebo
EULAR2019	临床2期	原发性干燥综合征 anti-Ro \| IFN gene expression signature	-	RSLV-132 10 mg/kg IV	築艱獵艱糧鏇簾繭廠夢(網網顧獵餘鑰遞積餘積) = 壓憲鹹齋顧觸製遞願壓廠膚鑰積製淵鹽淵遞獵 (選願積積鑰鑰觸衊膚淵 ) 更多	-	2019-06-12
				Placebo	範顧艱顧壓選顧選鬱襯(齋鹹簾網繭繭鹽糧淵蓋) = 淵積構構網鹹膚襯襯膚齋選鹹鬱積獵簾鏇繭壓 (鏇膚範鹹鹹蓋觸繭膚糧 )